Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer

NCT05007132 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

153

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

BIOLOGICAL: Panitumumab 20 milligram/ML
BIOLOGICAL: Bevacizumab
DRUG: Trifluridine/Tipiracil Hydrochloride

Sponsor

Dominik Paul Modest